WO2020087896A1 - Polyuréthane dégradable médical ayant une activité antibactérienne et son application - Google Patents

Polyuréthane dégradable médical ayant une activité antibactérienne et son application Download PDF

Info

Publication number
WO2020087896A1
WO2020087896A1 PCT/CN2019/084743 CN2019084743W WO2020087896A1 WO 2020087896 A1 WO2020087896 A1 WO 2020087896A1 CN 2019084743 W CN2019084743 W CN 2019084743W WO 2020087896 A1 WO2020087896 A1 WO 2020087896A1
Authority
WO
WIPO (PCT)
Prior art keywords
diisocyanate
chitosan
lysine
molecular weight
polyurethane
Prior art date
Application number
PCT/CN2019/084743
Other languages
English (en)
Chinese (zh)
Inventor
张文芳
Original Assignee
凯斯蒂南京医疗器械有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201811263478.8A external-priority patent/CN109503797A/zh
Priority claimed from CN201910270022.2A external-priority patent/CN110038170A/zh
Application filed by 凯斯蒂南京医疗器械有限公司 filed Critical 凯斯蒂南京医疗器械有限公司
Publication of WO2020087896A1 publication Critical patent/WO2020087896A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08—Materials for coatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/42—Polycondensates having carboxylic or carbonic ester groups in the main chain
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/64—Macromolecular compounds not provided for by groups C08G18/42 - C08G18/63

Definitions

  • the invention belongs to the technical field of degradable biological materials, and in particular relates to a medical degradable polyurethane with antibacterial activity of chitosan or its derivatives and uses thereof.
  • Polyurethane materials are widely used in medical and health care, especially in recent years. Polyurethane materials are widely implanted in patients as medical devices and artificial organs. However, inflammatory reactions often occur after implantation. The infection caused by this situation is usually difficult to rely on traditional antibacterial measures for treatment, causing great pain to the patient and greatly reducing the success rate of surgery. Therefore, research and development of polyurethane materials with excellent antibacterial properties is the majority of scientific research work The goal of the fight. The material is modified by introducing antibacterial groups, and the antibacterial groups of antibacterial agents are introduced into the polyurethane material through physical modification, chemical modification or composite modification, and the purpose of finally maintaining the antibacterial surface of the material is currently commonly used. Research methods.
  • degradable polyurethanes such as 1,6-hexamethylene diisocyanate (HDI) as the hard segment, polycarbonate diol (PCDL) as the soft segment, and lysine ethyl Polyester synthesized by ester hydrochloride (Lys-OEt) as a chain extender; L-lysine is used as a raw material to convert carboxyl groups on L-lysine to ester groups to synthesize L-lysine di
  • Polyurethane obtained by copolymerizing isocyanate (LDI) with different molecular weight polyethylene glycol (PEG) or hydroxyethylpiperazine (HEP); poly ( ⁇ -caprolactone) glycol with molecular weight of 2000 (PCL ) React with LDI to form prepolymer, and then react with chain extender 1,4-butanediol (BDO) to synthesize polyurethane (PU), etc.
  • HDI 1,6-hexamethylene diisocyan
  • More typical patent documents such as 200580014001.0 disclose a degradable polyurethane prepared by one-step method, mainly used to generate polyurethane elastomers with low modulus, and the reaction product is difficult to control, and the molecular weight of the obtained product is wide; general industrial production High-performance polyurethanes mostly use a two-step method. First, polyester or polyether polyol is first reacted with diisocyanate to form a prepolymer, and then diol or diamine chain extension is used to generate polyurethane. The resulting elastomer has a regular molecular structure and mechanical properties. It is better, the repeatability is good, and the product performance is easy to control. For this reason, the present invention uses a two-step method to prepare a high-performance polyurethane with antibacterial properties and controllable elongation at break.
  • chitosan and its derivatives have been recognized and studied for their bactericidal effect, especially in the field of medicine. The results are different from the changes in environmental conditions.
  • the main reason for the analysis is that the effective gene N of chitosan may be related to lipids and eggs on the bacterial cell membrane.
  • the white matter complex reacts, denatures the protein, changes the permeability of the cell membrane, or forms a negatively charged environment with the bacterial cell wall (especially the gram-positive bacteria cell wall is thick, compact, and rich in phosphoric acid), chitosan The integrity of the cell wall is damaged, or the cell wall tends to dissolve until the cell dies.
  • Chitosan contains hydroxyl and amino groups and can be chemically modified, such as quaternary ammonium groups Grafting, sulfonation, phosphorylation, alkylation, hydroxyethylation, loading of natural active substances, loading of metals or oxides, etc. to change the properties of chitosan, such as the preparation of carboxymethyl chitosan, improve water solubility Sex and bacteriostasis, with good film-forming properties.
  • chitosan antibacterial agents such as physical modification, chemical modification, and composite modification.
  • the agent and polyurethane prepolymer are modifiers.
  • water-soluble chitosan is modified.
  • Another example is the use of surface light grafting to modify chitosan.
  • Synthesis of azide-p-benzoic acid is first carried out. Nitro-p-benzoic acid introduces an azide group into the natural antibacterial agent chitosan and the hydrophilic modifier polyethylene glycol to synthesize azide chitosan and azide polyethylene glycol.
  • chitosan and polyethylene glycol were grafted onto polyurethane by light grafting to make the surface of the polyurethane have antibacterial properties and anti-adhesion; there are also reports in the literature on the preparation of chitosan-based water-based by chemical grafting method. Polyurethane resin, but using chitosan or its derivatives as chain extenders, the degradable medical polyurethane prepared by the two-step method has not been reported.
  • the invention first synthesizes the polyurethane prepolymer through a two-step method, and then directly cross-links with chitosan to obtain a degradable polyurethane with antibacterial effect.
  • This polyurethane has both degradability, good antibacterial properties and better mechanics. Performance and Young's modulus have very broad prospects for application in implanted medical products.
  • the technical problem to be solved by the present invention is to provide a medical degradable polyurethane with antibacterial activity and its use.
  • the polyurethane prepolymer is synthesized by a two-step method, and then cross-linking reaction with chitosan directly to obtain an antibacterial effect.
  • Degradable polyurethane this polyurethane has both degradability, good antibacterial properties, good mechanical properties and Young's modulus, and has a very broad expected application prospect in implanted medical products.
  • the invention discloses a medical degradable polyurethane with antibacterial activity, using chitosan or its derivatives as chain extenders, wherein the content of molecular chain fragments of chitosan or its derivatives in the macromolecule of polyurethane is 0.05- 50%.
  • the medical degradable polyurethane with antibacterial activity adopts chitosan or its derivatives as chain extenders, and the viscosity average molecular weight range of chitosan is: 1000-200,000, and the molecular chain fragments of chitosan or its derivative components
  • the content in the polyurethane macromolecule is 0.05-30%, and the degree of deacetylation in chitosan or its derivatives is greater than 50%.
  • the medical degradable polyurethane with antibacterial activity wherein the soft segment is a polymer formed by polymerizing one or more of GA, LA, PDO, CL and PEG, and the hard segment is selected from diisocyanate, hard
  • the segment is specifically selected from 1,6-hexamethylene diisocyanate, isophorone diisocyanate, and lysine polyisocyanate (which may contain a carboxyl group, or it may be a carboxyl group grafted with a hydroxyl group to form an ester group to form a certain lysine ester di (Isocyanate) or lysine triisocyanate, cis-cyclohexane diisocyanate, trans-cyclohexane diisocyanate, 1,4-butane diisocyanate, butane diisocyanate, 1,2-ethane diisocyanate, 1,3-propane diisocyanate, 4,4'-methylene-bis (cyclo
  • the medical degradable polyurethane with antibacterial activity wherein the soft segment is one or more than two polymers of GA, LA, PDO, CL and PEG, and the hard segment is selected from isocyanate (diisocyanate or triisocyanate) ), Specifically selected from 1,6-hexamethylene diisocyanate, isophorone diisocyanate, lysine diisocyanate or its carboxyl derivative (such as lysine ester diisocyanate, such as lysine fatty acid Ester diisocyanate, in which the number of carbon atoms of fatty acids is 1-30, such as methyl lysine diisocyanate, ethyl lysine diisocyanate, propyl lysine diisocyanate, butyl lysine diisocyanate, lysine Amino acid 18 fatty acid ester diisocyanate), lysine triisocyanate, 1,4-butane di
  • the medical degradable polyurethane with antibacterial activity according to the present invention is prepared by a two-step method to control the degradation time and elastic modulus of polyurethane.
  • the specific preparation method is as follows:
  • the soft segment is selected from one or two polymers of GA, LA, PDO, CL, glycol and PEG (molecular weight 200-2000), and the hard segment is selected from one of diisocyanate or triisocyanate, preferably lysine Acid isocyanate and one of its carboxyl derivatives (such as LDI, LTI), IPDI, HDI or 1,3-propane diisocyanate, the chain extender is selected from chitosan or carboxymethyl chitosan One (viscosity average molecular weight 200-100,000, deacetylation degree greater than 50%), the synthesis scheme is as follows:
  • the soft segment compound or composition and catalyst in the vacuum reaction bottle according to the feeding amount, put it in an oil bath at 70-140 ° C and react for 4-24h to obtain a linear polymer, and then weigh the appropriate proportion of isocyanate to react 0.5 -12h, dissolve with appropriate solvent or directly add chitosan or its derivatives as chain extender, evacuate and seal the bottle mouth, put it in an oil bath at 50-120 °C and react for 1-24h to obtain the final product,
  • the soft segment is selected from PPDO, PCL, PEG, PLA, PGA, PLGA, or any two copolymers or blends thereof, such as PDO and PGA copolymers, PDO and PCL copolymers, PLGA and PCL
  • the copolymer, chain extender is selected from chitosan or its derivatives, the synthesis scheme is as follows:
  • Anhydrous PPDO (molecular weight 1000-200,000), PEG (molecular weight 200-2000), PCL (molecular weight 1000-200,000), PLA (molecular weight 1000-200,000), PGA (molecular weight 1000-200,000), PLGA (molecular weight 1000-200,000), PDO and PGA copolymer (molecular weight of 1000-200,000) or copolymer of PCL and PDO (molecular weight of 1000-50,000), add the catalyst to the vacuum reaction bottle, add the appropriate proportion of LDI or LTI, Put it in an oil bath at 30-160 °C for 4-24h, dissolve it with an appropriate solvent or directly add chitosan or its derivatives, put it in a vacuum reaction bottle, evacuate and seal the bottle mouth, put it in 50-150 Reaction in an oil bath at °C for 2-24h to obtain the final product;
  • the catalyst is selected from one of stannous octoate, organic zinc or organic bismuth salt, and the dosage is 0.001-10wt% of the total feed amount;
  • the organic solvent is selected from fatty alcohol, DMSO, DMF, 1, 4-di One of oxane, ethyl acetate, ethyl octanoate, n-butanol, isobutanol, xylene and toluene;
  • the diol is selected from glycol or triol, specifically selected from ethylene glycol, Diethylene glycol, tetraethylene glycol, 1,3-propanediol, 1,4-butanediol, 1,5-pentanediol, 1,6-hexanediol, 1,7-heptanediol, 1,8- One or two of octanediol, 1,9-nonanediol, 1,10-decanediol
  • the implanted medical product further includes a contrast agent
  • the contrast agent is selected from: commonly used radioactive contrast agents (positive and negative contrast agents) and the like , Also includes zirconium, barium, iodine, manganese, iron, lanthanum, cerium, praseodymium, etc. combined or complex form of ionic form, preferably a contrast agent containing barium or iodine, preferably zirconium dioxide, barium sulfate and iodine preparations One kind.
  • the medical degradable polyurethane with antibacterial activity according to the present invention can be added with therapeutically active substances, such as small molecule compounds, plant extracts, polypeptides, proteins and various medicines, according to clinical needs.
  • therapeutically active substances such as small molecule compounds, plant extracts, polypeptides, proteins and various medicines, according to clinical needs.
  • Chitosan or its derivatives in medical degradable polyurethane with antibacterial activity refer to various chemical modifications of the hydroxyl and amino groups in chitosan, specifically including quaternary ammonium groups Polymer compound obtained by modification of grafting, sulfonation, phosphorylation, alkylation, hydroxyethylation, loading of natural active material, loading of metal or oxide.
  • the chitosan or its derivative in medical degradable polyurethane with antibacterial activity according to the present invention can be used as a drug carrier, and can be directly mixed with drugs after being made into various drug preparations or microspheres according to the conventional preparation process. It can be made into microspheres first, and then loaded with active molecules, active factors, stem cells or drugs during use.
  • the lysine isocyanate and its carboxyl derivative of the present invention wherein the lysine diisocyanate may contain a carboxyl group or may be grafted with a compound containing a hydroxyl group to form an ester group, such as lysine methyl ester diisocyanate and lysine Ethyl acid diisocyanate, lysine propyl diisocyanate, lysine butyl diisocyanate, lysine carboxyl and any of the 20 common amino acids to form an ester bond compound, such as lysine arginine, Lysine prolyl ester, lysine tyrosine ester, lysine histidine ester, or lysine triisocyanate, preferably lysine diisocyanate, lysine methyl ester diisocyanate, lysine ethyl ester One of diisocyanate and propyl lysine.
  • the medical degradable polyurethane with antibacterial activity according to the present invention can be used as a medical material to prepare implants or interventional instruments, the medical implant material can be used alone, and can be compounded with other polymer materials to form a composite, It can be used for implantation equipment and its coating, implantable artificial organ and its coating, contact artificial organ and its coating, stent and its coating, interventional catheter and its coating, artificial skin, tissue engineering stent and The coating materials of organ assisting devices, when used as medical implants or intervention materials, need to be further purified to remove residual toxic monomers, catalysts or organic solvents.
  • the chitosan or its derivative in medical degradable polyurethane with antibacterial activity can be made into a composite with metal materials or non-metallic materials such as polymer materials, and made by various processes suitable for blood vessels, Vein, esophagus, biliary tract, trachea, bronchus, small intestine, large intestine, urethra, ureter, or other implantable medical device products close to the tubular body channel, such as vascular stent, tracheal stent, bronchial stent, urethral stent, esophageal stent, biliary stent, Ureteral stent (double J tube), ureteral narrow stent, stent for small intestine, stent for large intestine, larynx implant, bypass catheter or ileostomy etc.
  • metal materials or non-metallic materials such as polymer materials
  • Specific applications include: implant equipment, implantable artificial organs, contact artificial organs, stents, interventional catheters, and organ assist devices, including bone plates, nails, bone needles, bone rods, spinal internal fixation equipment, and ligatures , Patella, bone wax, bone repair materials, cerebral aneurysm clips, silver clips, vascular anastomosis clips (plastic), plastic materials, heart or tissue repair materials, intraocular filling materials, birth control rings, nerve patches; implantation Specific artificial organs include: artificial esophagus, artificial blood vessel, artificial vertebral body, artificial joint, artificial urethra, artificial valve, artificial kidney, artificial breast, artificial skull, artificial jaw, artificial heart, artificial tendon, artificial cochlea, artificial anus closure Touch; artificial organs specifically include: artificial larynx, artificial skin, artificial cornea; stent vessels include: stent, prostate stent, biliary stent, esophageal stent and ureteral stent; organ assist devices include: implanted hearing aid
  • polyurethane disclosed in this invention with antibacterial activity using chitosan or its derivatives as chain extenders can be made into composite materials with polymer materials according to the physical and chemical performance requirements of implanted medical devices, such as: polylactic acid, Polycaprolactone, polyparadioxanone and its copolymers (PPDO, PLA-PDO) polyparadioxanone (PPDO), polytrimethylene carbonate, polylactic acid-trimethylene carbonate Ester copolymer, polycaprolactone-trimethylene carbonate copolymer, polyglycolic acid, polylactic acid-glycolic acid copolymer, polyether ether ketone, polyvinylpyrrolidone and / or polyethylene glycol, polyvalerolactone, Poly- ⁇ -decalactone, polylactide, polyglycolide, copolymers of polylactide and polyglycolide, poly- ⁇ -caprolactone, polyhydroxybutyric acid, polyhydroxybutyrate, polyhydroxy
  • the polyurethane material with antibacterial activity can be added with commercially available or published polypeptides, proteins and active ingredients, including anti-proliferation, anti-migration, anti-angiogenesis, anti-inflammatory, etc. according to clinical needs.
  • Physiologically active drugs such as sirolimus, everolimus, pimecrolimus, meflandin, ifosfamide, ifosfamide, phentermine, anti-inflammatory, cell growth inhibitory, cytotoxic or antithrombotic Nitrogen mustard, bendamustine, somatostatin, tacrolimus, roxithromycin, daunorubicin, ascomycin, bafaromycin, romustine, cyclophosphamide, estramustine Stin, dacarbazine, erythromycin ethosin, medicamentn, salinomycin, concanavalin, clarithromycin, oleancin, vinblastine, vincristine, vindesine, vinblastine Repin, etoposide,
  • the raw materials used in this example are processed in advance to a moisture content of less than 100 ppm and are ready for use.
  • Option 1 Weigh 1g 1.3-propanediol and 59g CL into the test tube, add a drop of T-9 (0.01-0.1wt%) as a catalyst, then add a magnetic stirrer, vacuum / nitrogen cycle 3 At the same time, the tube mouth was sealed under vacuum and placed in an oil bath at 120-140 ° C for 24 hours to obtain a linear polymer. Then weigh 7g L-lysine methyl ester diisocyanate and 5g chitosan (molecular weight 2000-10000), put into a test tube, evacuate and seal the tube. Place in an oil bath at 70-90 ° C for 4-6h to obtain the final product. (The resulting product: molecular weight between 50,000 and 60,000, Young's modulus is large, and the elasticity is poor)
  • Option 2 Weigh 1g 1.3-propylene glycol and 35g CL into test tubes, add one drop of T-9 (0.1-0.6wt%) as a catalyst, and then add a magnetic stirrer, vacuum / nitrogen filling cycle 3 At the same time, the tube mouth was sealed under vacuum and placed in an oil bath at 110-140 ° C for 18-24 hours to obtain a linear polymer. Then weigh 5.7g L-lysine ethyl ester diisocyanate and 2.4g chitosan (molecular weight 5000-20000), put into a test tube, evacuate and seal the tube. Put it in an oil bath at 70-80 ° C for 3-5 hours to obtain the final product. (Product obtained: molecular weight between 60,000 and 90,000, Young's modulus is relatively large, and elasticity is average)
  • Test tube mouth put in an oil bath at 110 °C for 12 hours to obtain linear polymer, weigh 3g L-lysine ethyl ester diisocyanate and 0.6g carboxymethyl chitosan (molecular weight 50,000-70,000), put Into a vacuum reaction bottle, evacuation / nitrogen filling cycle 3 times to evacuate and seal the bottle mouth, put in an oil bath at 70 °C for 4h to obtain the final product (the resulting product: molecular weight of 15-190000, Young's mold Larger volume, better elasticity)
  • the medical degradable polyurethane developed with the antibacterial activity developed by the method disclosed by the present invention can be used as a drug carrier, can be directly mixed with drugs and prepared into various drug preparations or microspheres according to conventional preparation processes, and can also be used to make micro
  • the medicine is attached after the ball, and the preparation process and scheme are as follows:
  • the preparation process can be as follows:
  • the polyurethane material of the present invention is dissolved in an organic solvent (such as ethyl acetate, dichloromethane or chloroform solution), and the formulated concentration is 1-30%. Take 1 portion and slowly add a dispersant such as carboxymethyl chitosan solution In 5-20 parts of (0.1-5%), PVA (0.1-5% solution) or its salt solution, stir to evaporate the organic solvent to form microspheres, and obtain microspheres with uniform particle size after sieving and filtration.
  • an organic solvent such as ethyl acetate, dichloromethane or chloroform solution
  • a dispersant such as carboxymethyl chitosan solution
  • PVA 0.1-5% solution
  • its salt solution stir to evaporate the organic solvent to form microspheres, and obtain microspheres with uniform particle size after sieving and filtration.
  • microspheres are repeatedly washed with water for injection, and an appropriate amount of excipient is added to obtain the filled microspheres that can be injected.
  • the polyurethane material of the present invention Take the polyurethane material of the present invention and paclitaxel (the weight percentage with the polyurethane material is 0.01: 0.1-50) dissolved in an organic solvent (such as ethyl acetate, dichloromethane or chloroform solution), the formulated concentration is: 1-30%, Take 1 part and slowly add a dispersant such as carboxymethyl chitosan solution (0.1-5%), small molecule chitosan acid solution, PVA (0.1-5% solution) or its salt solution, 5-20 parts, The volatile organic solvent was stirred to form microspheres, and after screening and filtering, a sustained-release microsphere with paclitaxel loaded with uniform particle size was obtained.
  • an organic solvent such as ethyl acetate, dichloromethane or chloroform solution
  • the antibacterial and anti-adhesion coating for the long-term indwelling central venous catheter is prepared as follows:
  • the antibacterial polyurethane material in Examples 1, 2 or 10 of the present invention is formulated with an organic solvent (preferably one of ethyl acetate, dichloromethane or chloroform) into a 0.1-10% solution, sprayed or dipped in Insert the vein indwelling part, dry it and polish it.
  • an organic solvent preferably one of ethyl acetate, dichloromethane or chloroform
  • the preparation process is as follows:
  • the composite material prepared in (3) is dipped or sprayed with a hydrophilic coating (such as an aqueous solution made of chitosan, hyaluronic acid, collagen, cellulose, etc.), dried, polished, and polished.
  • a hydrophilic coating such as an aqueous solution made of chitosan, hyaluronic acid, collagen, cellulose, etc.
  • a 3D printer with two feeding devices is selected, one feeding device is added with PMMA (powder particle size 30-80um) bone cement mixed solution, and the other feeding device is added with the composite material of antibacterial polyurethane material and PVP of the present invention.
  • Chloroform is configured as a solution with a percentage concentration of 10-30%), print out the stent of the set size and shape, wash it with water for injection and dry it.
  • Example 29 The polyurethane obtained by the above reaction was dissolved with chloroform, laid into a 0.5 mm thick film, cut into a 1 cm ⁇ 5 cm film block, tested for fracture productivity and simultaneously placed in PBS solution, incubated at 37 degrees, and observed degradation experiments , The results are as follows:
  • Escherichia coli (8099) and Staphylococcus aureus (ATCC 6538) were used as representative strains of Gram-negative and Gram-positive bacteria, and the antibacterial effect of the samples was determined by the absorption method.
  • the bacteria were inoculated in nutrient broth and cultured at 37 ° C for 24 hours. The concentration of the bacterial solution was adjusted to the usual concentration. 0.1 ml of bacterial solution was inoculated into the PBS solution of the degraded material and incubated at 37 ° C for 24 hours. After that, 20 ml of soybean casein digested lecithin polysorbate (SCDLP) medium was added to rinse the sample, and the number of bacteria was counted by the plate counting method. Use pure cotton gauze as a control sample. According to the equation to determine the bacteriostatic value, it can be seen from the experimental results that the antibacterial material prepared by the present invention has a good antibacterial effect.
  • SCDLP soybean casein digested lecithin polysorbate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention concerne un polyuréthane dégradable médical ayant une activité antibactérienne et une application de celui-ci, notamment un polyuréthane dégradable médical contenant du chitosane ou un dérivé de celui-ci, un procédé de préparation du polyuréthane et une application du polyuréthane dans un matériau biologique d'implant. Des polyuréthanes dégradables médicaux ayant une activité antibactérienne, différents poids moléculaires et propriétés de dégradation peuvent être conçus et synthétisés selon les exigences de la médecine régénérative et des dispositifs médicaux implantés dans le corps.
PCT/CN2019/084743 2018-10-28 2019-04-28 Polyuréthane dégradable médical ayant une activité antibactérienne et son application WO2020087896A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN201811263478.8A CN109503797A (zh) 2018-10-28 2018-10-28 一种具有抗菌活性的医用可降解聚氨酯及其用途
CN201811263478.8 2018-10-28
CN201910270022.2 2019-04-04
CN201910270022.2A CN110038170A (zh) 2019-04-04 2019-04-04 一种可降解聚氨酯复合物及其用途
CN201910270521 2019-04-04
CN201910270521.1 2019-04-04

Publications (1)

Publication Number Publication Date
WO2020087896A1 true WO2020087896A1 (fr) 2020-05-07

Family

ID=70463625

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/084743 WO2020087896A1 (fr) 2018-10-28 2019-04-28 Polyuréthane dégradable médical ayant une activité antibactérienne et son application

Country Status (1)

Country Link
WO (1) WO2020087896A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111499862A (zh) * 2020-05-14 2020-08-07 管善月 一种可降解聚氨酯及其制备方法
CN114163806A (zh) * 2021-11-29 2022-03-11 浙江大学台州研究院 一种抗菌多糖外表面改性tpu医用导管及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1869094A (zh) * 2006-05-16 2006-11-29 南京大学 壳聚糖改性水性聚氨酯弹性体的制备方法
CN101343346A (zh) * 2008-09-05 2009-01-14 寇世杰 壳聚糖聚氨酯材料及其制备方法
CN101402718A (zh) * 2008-11-24 2009-04-08 中国人民解放军总后勤部军需装备研究所 一种人体皮肤传热性能等效材料的制备方法
CN101497698A (zh) * 2009-01-22 2009-08-05 南京大学 壳聚糖-聚氨酯离子复合物弹性体材料的制备方法
CN103420868A (zh) * 2013-08-05 2013-12-04 四川大学 含双季铵盐二胺或二醇单体及制备方法和由其制备的水性无毒抗菌聚氨酯乳液及方法
WO2015017847A1 (fr) * 2013-08-02 2015-02-05 International Park Of Creativity Biomousses de polyuréthane dérivées de produits naturels et procédés de fabrication et d'utilisation de ces dernières
CN109503797A (zh) * 2018-10-28 2019-03-22 凯斯蒂南京医疗器械有限公司 一种具有抗菌活性的医用可降解聚氨酯及其用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1869094A (zh) * 2006-05-16 2006-11-29 南京大学 壳聚糖改性水性聚氨酯弹性体的制备方法
CN101343346A (zh) * 2008-09-05 2009-01-14 寇世杰 壳聚糖聚氨酯材料及其制备方法
CN101402718A (zh) * 2008-11-24 2009-04-08 中国人民解放军总后勤部军需装备研究所 一种人体皮肤传热性能等效材料的制备方法
CN101497698A (zh) * 2009-01-22 2009-08-05 南京大学 壳聚糖-聚氨酯离子复合物弹性体材料的制备方法
WO2015017847A1 (fr) * 2013-08-02 2015-02-05 International Park Of Creativity Biomousses de polyuréthane dérivées de produits naturels et procédés de fabrication et d'utilisation de ces dernières
CN103420868A (zh) * 2013-08-05 2013-12-04 四川大学 含双季铵盐二胺或二醇单体及制备方法和由其制备的水性无毒抗菌聚氨酯乳液及方法
CN109503797A (zh) * 2018-10-28 2019-03-22 凯斯蒂南京医疗器械有限公司 一种具有抗菌活性的医用可降解聚氨酯及其用途

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111499862A (zh) * 2020-05-14 2020-08-07 管善月 一种可降解聚氨酯及其制备方法
CN111499862B (zh) * 2020-05-14 2022-03-18 深圳市兰蒂斯科技有限公司 一种可降解聚氨酯及其制备方法
CN114163806A (zh) * 2021-11-29 2022-03-11 浙江大学台州研究院 一种抗菌多糖外表面改性tpu医用导管及其制备方法

Similar Documents

Publication Publication Date Title
CN109503797A (zh) 一种具有抗菌活性的医用可降解聚氨酯及其用途
WO2019076178A1 (fr) Polyuréthane médical dégradable ajustable en termes d'allongement à la rupture et à temps de dégradation réglable
WO2017054433A1 (fr) Composition de polyuréthane à module d'élasticité ajustable, composite d'échafaudage et son procédé de préparation
JP5153340B2 (ja) 薬剤放出制御組成物および薬剤放出性医療器具
ES2451653T3 (es) Dispositivo médico implantable con revestimiento de suministro de fármacos de poliéster de erosión superficial
US20210128795A1 (en) Spiral coated stent with controllable gradient degradation, preparation method thereof and application thereof
CN105169496A (zh) 一种可降解支架组合物
CN104623740B (zh) 一种药物球囊及其制备方法
JP6147906B2 (ja) 薬剤バルーン用組織接着コーティング
JP2010518945A (ja) 長期埋込み用の医用物品
CN109939271B (zh) 一种医用生物可降解锌合金支架的涂层结构及其制备方法
JP2005530561A (ja) 薬剤送達用シリコーン混合物及び複合体
JP2015221204A (ja) 自己消失性コーティング
US8871819B2 (en) Glycerol ester active agent delivery systems and methods
CN100577221C (zh) 血管支架的表面改性涂层及其制备方法
WO2020087896A1 (fr) Polyuréthane dégradable médical ayant une activité antibactérienne et son application
Wang et al. 3D printing of multi-functional artificial conduits against acute thrombosis and clinical infection
CN106620897B (zh) 一种抗再狭窄的管腔内支架材料
CN107865868B (zh) 氨来呫诺的新用途
CN115558078A (zh) 一种可降解聚氨酯及其用途
CN101641059A (zh) 一种不对称药物控释涂层冠脉内支架
JP4851086B2 (ja) 埋め込み型医用機器用のコーティング用組成物及び該機器をコーティングする方法
CN107865983B (zh) 一种药物支架及其制备方法
CN210301826U (zh) 一种医用生物可降解锌合金支架的涂层结构
CN114082000B (zh) 一种可生物降解载药高分子材料支架及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19878301

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19878301

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 03/12/2021)

122 Ep: pct application non-entry in european phase

Ref document number: 19878301

Country of ref document: EP

Kind code of ref document: A1